Gilead Sciences (GILD) has agreed to acquire biotechnology company Arcellx (ACLX) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an ...

Gilead has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval.

Arcellx, Inc. (NASDAQ:ACLX) is among the 12 Best Performing Stocks in February. On February 23, 2026, CNBC reported that ...

Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.

This sale of 89,916 shares is notably larger than his historical median sell size of 38,300 shares since January 2025. What ...

Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in ​its largest deal since 2020, the ​biopharma company said on ​Monday.

Gilead Sciences has shored up its position in cell therapies for cancer with a deal to acquire Arcellx, a company it has been working with since 2022, taking full control of a CAR-T therapy for ...

The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.

Arcellx Inc. will report fourth-quarter results Monday, likely its final earnings release as an independent company before ...

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

Biotech heavyweight Gilead Sciences is set to acquire a Rockville-area cancer therapy developer in a deal valued at nearly $8 billion. The California-based drugmaker announced Monday that it will buy ...

Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock’s move wasn’t ...